Albumin-bound paclitaxel as new treatment for metastatic cholangiocarcinoma: A case report

World Journal of Clinical Oncology
Roberto Martin HuertasMercedes Rodríguez-Garrote

Abstract

Cholangiocarcinomas are rare and very aggressive tumors. Most patients have advanced-stage or unresectable disease at presentation, and the systemic therapies have limited efficacy. Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free taxane that has been approved for the treatment of some cancers such as breast, non-small cell lung and pancreatic cancer, however it has not been applied to treat cholangiocarcinoma. We have both preclinical and clinical evidence of the efficacy of nab-paclitaxel in cholangiocarcinoma, yet no phase 3 trials have been made. A 63-year-old man was diagnosed in December 2016 with stage III B intrahepatic cholangiocarcinoma. Surgery was performed, followed by adjuvant chemotherapy treatment with capecitabine and gemcitabine; although, the gemcitabine was suspended due to allergic reaction after two cycles. In April 2019, metastatic cholangiocarcinoma relapse was diagnosed, and a first-line treatment with FOLFOX scheme was started. Eight cycles were administered, producing an initial clinical improvement and decrease in blood tumor marker levels. Radiological and serological progression was noted in September 2019. As a second-line treatment, FOLFIRI was not recommended due to risk of worsening ...Continue Reading

References

May 1, 1994·Seminars in Liver Disease·J N Vauthey, L H Blumgart
Oct 1, 1996·Annals of Surgery·A NakeebJ L Cameron
Jun 8, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T Patel
Sep 27, 2001·Annals of Surgery·W R JarnaginL H Blumgart
May 5, 2004·Journal of Hepatology·Yasser H ShaibHashem B El-Serag
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharJoyce O'Shaughnessy
Apr 26, 2007·Annals of Surgery·Michelle L DeOliveiraRichard D Schulick
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharPaul Bhar
Apr 9, 2010·The New England Journal of Medicine·Juan ValleUNKNOWN ABC-02 Trial Investigators
Jun 19, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Denise A Yardley
Oct 22, 2013·Gastroenterology·Sumera Rizvi, Gregory J Gores
Aug 27, 2016·Journal of Gastrointestinal Oncology·Matthias UnseldGerald W Prager
Jun 5, 2018·Annals of Translational Medicine·Georgios TsironisMeletios-Athanasios Dimopoulos
Apr 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sibylle LoiblCarsten Denkert
Jan 9, 2020·Molecular Cancer Therapeutics·Melanie A KrookSameek Roychowdhury

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

GeparSepto

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Gastroenterology
Konstantinos N Lazaridis, Gregory J Gores
Ryōikibetsu shōkōgun shirīzu
M Komatsu, O Masamune
Der Internist
J SchmielauW Schmiegel
Best Practice & Research. Clinical Gastroenterology
Arndt Vogel, Michael P Manns
© 2021 Meta ULC. All rights reserved